Prince Harry reportedly wants to work on his relationship with Kate Middleton. According to an insider, he seemingly would want to mend fences with his sister-in-law. It was said that Prince William "won't speak to him." Therefore, Harry might try to seek Middleton's help to make amends with his brother.
For those unversed, the Duke of Sussex has returned to the UK with his wife, Meghan Markle. They arrived on August 26 with their kids, Prince Archie and Princess Lilibet.
Prince Harry would reportedly like to repair his and Kate Middleton's relationship. They used to share a close, comfortable bond. But things turned sour after the Sussexes moved to California. Now, they have returned to the duke's homeland; therefore, Harry might want to make amends with his sister-in-law.
A source told the National Examiner that Harry would approach Middleton even if he had to do it behind his brother's back. He seems to believe that the Princess of Wales can help her mend fences with Prince William. "With everything that is going on, Harry feels he needs to have some sort of dialogue with his brother's camp, and since William won't speak to him, it just makes sense to go to Kate," they said.
Furthermore, the insider suggested that Harry thinks Middleton will need the "most straightforward path" to reach out to the royals. "He hates to put her in the middle, but he says he doesn't feel like he has any other choice because William is continuing to be so stubborn." According to them, the future queen seemed to be "more reasonable" than her husband.

#according #therefore #reportedly #relationship

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was up 7.5% in after-hours trading as of approximately 5:33 p.m. ET Wednesday after the FDA approved Genglycos for glycogen storage disease type Ia, or GSDIa. The one-time gene therapy is the first approved treatment designed to address the disorder's underlying cause. It will carry a U.S. list price of approximately $2.7 million per patient and is expected to become available through qualified treatment centers within 30 to 60 days.
The approval gives Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) first-mover status in a disease the company estimates affects only 1,500 to 2,500 Americans. The commercial question is whether a high-priced treatment for an ultra-rare population can produce meaningful revenue after diagnosis, reimbursement, and treatment-center constraints.
GSDIa prevents the liver from releasing glucose properly, leaving patients dependent on frequent raw-cornstarch doses to avoid potentially life-threatening hypoglycemia. In the Phase 3 GlucoGene trial, Genglycos reduced mean daily cornstarch intake by 41% at Week 48, compared with 10% for placebo, while maintaining glucose control. For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), reducing that daily burden creates a clear argument for premium pricing.
Longer-term data also support the treatment's potential durability. At Week 96, the original-treatment group reported a 61% mean reduction from baseline, while the crossover group reported a 61% reduction from Week 48, when it began treatment. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will manufacture the therapy at its Bedford, Massachusetts, facility, giving the company direct control over an important part of the supply chain.
The launch will also test infrastructure that could support future gene therapies. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) already sells rare-disease products including Crysvita, Dojolvi, Evkeeza and Mepsevii. Second-quarter revenue reached $214 million, while cash, cash equivalents, and marketable securities totaled $436 million as of June 30. Genglycos therefore enters a functioning commercial organization rather than a first-time launch platform.

#rare #pharmaceutical

BLOOMINGTON — Sam Alexis' eligibility for the forthcoming college basketball season was thrown in doubt Wednesday, when the Tennessee Court of Appeals issued a stay on a lower-court ruling granting several athletes an injunction against the NCAA's application of its new age-based eligibility model.
Alexis is one of a number of players who graduated high school in 2022 and played four years of college sports in that same ****** e of time seeking relief against the NCAA's decision to apply its new five-years-to-play-five rule only to athletes beginning with the ongoing academic year. Athletes across several sports and in several states have won relief against the ****** ociation's decision, granting those athletes an additional year of eligibility as well.
One of several athletes party to that filing, Alexis gained his fifth year when the Chancery Court of Davidson County, Tennessee, granted its injunction earlier this summer. Alexis played his first two years of college basketball at Chattanooga.
Indiana welcomed Alexis back into an open 13th scholarship, after coach Darian DeVries elected to leave one spot unfilled following his roster rebuild last spring. Now, Alexis' eligibility for 2026-27 is in limbo once more.
The appellate-court stay does not overrule the lower court's injunction. It simply stayed the injunction, and therefore the relief it provided plaintiffs in Alexis' case, while the higher court considers the NCAA's appeal.

#several #years #relief #year

Coty Inc. (NYSE:COTY) traded about 7% lower shortly after its earnings release, with the after-hours decline later approaching 8.5%, as a fourth-quarter revenue beat was accompanied by a wider-than-expected adjusted loss and weaker near-term profit guidance. Revenue increased 1.3% to $1.27 billion, outperforming the consensus forecast for a 4.6% decline. However, the company-defined adjusted loss was $0.02 per share versus the $0.01 consensus loss, like-for-like sales fell 1%, and the reported net loss widened to $141 million.
The larger red flag is visibility. Coty Inc. (NYSE:COTY) expects first-quarter company-defined adjusted earnings of $0.11 to $0.13 per share, below the $0.14 consensus estimate, while like-for-like revenue is projected to decline by a low- to mid-single-digit percentage. Management also withheld fiscal 2027 guidance and described the period as a transition year, even though fiscal 2025 carried the same label.
The revenue beat showed that Coty Inc. (NYSE:COTY) still owns brands with meaningful consumer demand. Fourth-quarter like-for-like sales declined only 1%, improving substantially from the 7% decline in the third quarter. Fragrance demand remains comparatively resilient, supporting a portfolio centered on brands such as Burberry, Hugo Boss, Calvin Klein, Marc Jacobs and Chloé.
Portfolio simplification could also strengthen Coty Inc. (NYSE:COTY)'s balance sheet. Coty received $250 million at the signing of the Gucci Beauty agreement and is due another $150 million by September 30, 2027, subject to a possible holdback of up to $30 million. The immediate proceeds can support debt reduction and investment in core brands. Potential sales of CoverGirl, Rimmel, or other Consumer Beauty **** ets could further reduce complexity and concentrate capital on higher-return prestige fragrances.
The first-quarter outlook leaves Coty Inc. (NYSE:COTY) without a demonstrated earnings inflection point. Management is forecasting another like-for-like sales decline, adjusted earnings below consensus, and no full-year framework. Investors therefore lack a clear bridge between the restructuring program and sustainable earnings or free-cash-flow growth.

#coty #earnings #quarter #revenue

Michigan Democratic Senate nominee Abdul El-Sayed told Fox News host Jesse Watters on Monday that he would not defend the Green New Deal when confronted with his past support for the progressive climate proposal, a notable shift from years of publicly embracing it by name.
"Look, I'm not going to defend the Green New Deal," El-Sayed told Watters after the host confronted him over his past support for the proposal. When Watters reiterated that El-Sayed was on record supporting it, El-Sayed redirected the discussion toward lowering energy costs and creating Michigan jobs by prioritizing renewables.
Michigan, which Trump won in 2024 but lost in 2020, is shaping up to have one of the most competitive Senate races in the country, with the likely narrow results in the state potentially determining control of Congress. Critics charge that El-Sayed is downplaying some of his past beliefs and scrubbing his online footprint to appear more moderate, and therefore more palatable, to Michigan voters.
Unearthed Clip Exposes More Anti-police Rhetoric As El-sayed Gets Grilled For Deleting Social Media Posts
Though El-Sayed declined to defend the Green New Deal in front of a national audience, he previously hasn't been so shy.

#green #past

Jackie Goldschneider reportedly faced potential legal action over her communications with Vanessa Reiser. Attorney Doug Anton discussed the alleged situation on the Get Real With Kim D podcast, focusing on Jackie's legal background and messages with Luis Ruelas' ex-fiancée.
Doug Anton recently discussed the complicated history involving Vanessa Reiser and Luis Ruelas. The attorney claimed Jackie provided legal guidance during Vanessa's legal troubles. He also suggested those communications raised concerns about confidentiality and attorney-client privilege.
According to Anton's account, Jackie was not merely asking Vanessa questions. He said she also answered Vanessa's legal questions and discussed her situation. Anton interpreted their text messages as creating a relationship of trust.
The claims were discussed during a two-part episode of Get Real With Kim D. Kim DePaola hosted Anton and Reiser for the podcast episode. The discussion reportedly explored details that had not previously received much public attention.
Jackie previously worked as an attorney before joining The Real Housewives of New Jersey. Her legal background therefore became relevant to the allegations. Anton questioned whether her communications crossed a professional boundary.

#anton #Attorney #real

Real Madrid are expected to give Marc Cucurella his first start at the Santiago Bernabeu on Wednesday, with the summer signing in line to be the only alteration to Jose Mourinho's starting XI against Real Sociedad.
According to AS, Mourinho is not planning a major overhaul for Real Madrid's first home match of the 2026/27 La Liga season.
Instead, the Portuguese coach is expected to keep faith with a side close to his strongest available lineup, with Cucurella's introduction at left-back standing out as the key change.
The match could therefore offer the Bernabeu faithful their first proper look at one of the club's notable summer arrivals from the opening whistle.
Cucurella has already had his first taste of action in a Real Madrid shirt, coming off the bench against Espanyol, but Wednesday's clash against Real Sociedad is expected to mark his first start.

#real

It's a quiet but important week on the earnings front this week, with some key technology names set to report. This week we have Nvidia (NVDA), Marvell Technology (MRVL), Crowdstrike Holdings (CRWD) and Salesforce (CRM) all set to report.
Before a company reports earnings, implied volatility is usually high because the market is unsure about the outcome of the report. Speculators and hedgers create huge demand for the company's options which increases the implied volatility, and therefore, the price of options.
Nvidia Stock Is Treading Water Ahead of Earnings This Week - What's the Best NVDA Play?
Why the China-Led Weakness in NXP Semiconductors Stock Could Open Doors for Speculators
Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market **** ysis you won't find anywhere else.

#earnings #report #NVIDIA #technology

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was up 7.5% in after-hours trading as of approximately 5:33 p.m. ET Wednesday after the FDA approved Genglycos for glycogen storage disease type Ia, or GSDIa. The one-time gene therapy is the first approved treatment designed to address the disorder's underlying cause. It will carry a U.S. list price of approximately $2.7 million per patient and is expected to become available through qualified treatment centers within 30 to 60 days.
The approval gives Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) first-mover status in a disease the company estimates affects only 1,500 to 2,500 Americans. The commercial question is whether a high-priced treatment for an ultra-rare population can produce meaningful revenue after diagnosis, reimbursement, and treatment-center constraints.
GSDIa prevents the liver from releasing glucose properly, leaving patients dependent on frequent raw-cornstarch doses to avoid potentially life-threatening hypoglycemia. In the Phase 3 GlucoGene trial, Genglycos reduced mean daily cornstarch intake by 41% at Week 48, compared with 10% for placebo, while maintaining glucose control. For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), reducing that daily burden creates a clear argument for premium pricing.
Longer-term data also support the treatment's potential durability. At Week 96, the original-treatment group reported a 61% mean reduction from baseline, while the crossover group reported a 61% reduction from Week 48, when it began treatment. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will manufacture the therapy at its Bedford, Massachusetts, facility, giving the company direct control over an important part of the supply chain.
The launch will also test infrastructure that could support future gene therapies. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) already sells rare-disease products including Crysvita, Dojolvi, Evkeeza and Mepsevii. Second-quarter revenue reached $214 million, while cash, cash equivalents, and marketable securities totaled $436 million as of June 30. Genglycos therefore enters a functioning commercial organization rather than a first-time launch platform.

#treatment

Lewis Hamilton may be more emotionally invested in his rumored relationship with Kim Kardashian than she is, according to a body language expert. The Formula 1 champion and reality star have continued to fuel romance rumors through their recent public appearances and vacation photos. However, neither Hamilton nor Kardashian has publicly confirmed the romance. An ******* ysis of their recent interactions suggests that Hamilton's feelings may be growing stronger, while Kardashian appears more guarded.
Body language expert Inbaal Honigman ******* yzed the couple's recent interactions. According to RadarOnline, she observed that Hamilton's body language has grown noticeably warmer. She noted that his open gestures suggest a deepening connection.
The expert claimed Hamilton's expressions and body language indicate that he is becoming more emotionally invested. "In a couple of their recent vacation photos, Lewis's eyes begin to soften when he looks at Kim, and his hands around her have become gentler," Honigman reportedly observed.
She also pointed to the racing star's posture, saying his poses appear "closer" and "more devoted," suggesting that his emotions may be deepening. However, Honigman argued that Kardashian appears to be approaching the relationship differently.
According to the expert, the SKIMS founder remains primarily focused on her career, family, and public image. Therefore, her priorities create an emotional distance between the two. She continues to keep her personal brand at the forefront.

#recent #according #however

The final seven of the total 36 participants will be confirmed late on Wednesday evening after the end of the second-leg playoff matches. They will be divided into four pots of nine clubs each based on their UEFA coefficient. At the end of the 2025/26 season, Borussia Dortmund were 11th in the rankings with 100.750 points, topped by Bayern Munich, and will therefore be placed in pot two.
Placement in the four different pots has no direct impact on whether a club will face what are commonly referred to as "easy" or "difficult" opponents. A computer will draw two clubs from each of the four pots as opponents for each of the 36 participants in the league phase. Matches between two teams from the same **** ociation are not possible. This means BVB cannot face Bayern Munich, RB Leipzig or VfB Stuttgart in the league phase.
As in the previous two seasons, each club will play four home matches and four away matches. The results will go into one combined table featuring all 36 participants. The top eight teams will qualify directly for the round of 16, while the teams placed ninth to 24th will compete in a playoff format for the remaining eight spots in the last 16.
The league phase, consisting of eight matchdays, begins on 8 September 2026 and ends on 27 January 2027. The playoffs will be played from mid-February 2027.
The UEFA Champions League schedule, including match dates and kick-off times, will be announced by Saturday, 29 August at the latest. UEFA has announced that it will publish a corresponding notice on its social media channels shortly before the schedule is released.

#eight

Meghan Markle has reportedly developed a certain reputation while living in her Montecito mansion. Now, according to a new report, that reputation has allegedly made it difficult for the ******* ss of Sussex to hire housekeepers, as she and her family plan to move back to the UK. A representative for Meghan Markle and Prince Harry has reportedly confirmed their move to the UK to The New York Times. The rep has also allegedly clarified that the move will not be permanent.
Meghan Markle's reported reputation in Montecito has apparently been turning housekeepers away, ahead of their reported move to the UK. As reported by Page Six, an insider told the outlet that the ******* ss of Sussex "had trouble hiring maids because a lot of the housekeepers in Montecito didn't want to work for them." The source further claimed that "Meghan would interview people herself and could come across as really snobbish and rude." According to the insider, some of the housekeepers felt "so offended by the way she spoke to them that word started getting around."
Furthermore, the insider suggested that Meghan Markle's alleged reputation among Montecito housekeepers eventually became somewhat of "a running joke" across the luxurious California enclave. Per the magazine, the source claimed, "It got to the point where people would joke that all the maids in Montecito hated them."
Meghan Markle and Prince Harry moved to Montecito, California, after stepping down from their working royal duties and leaving their royal lives behind in Britain in 2020. They have been staying in their Montecito mansion with their two children, Prince Archie and Princess Lilibet, since then. Therefore, when reports of the Duke of Sussex and the ******* ss of Sussex moving back to the UK first emerged, the news raised eyebrows. The news came out just weeks after the Sussex couple reunited with King Charles and Queen Camilla at Highgrove House in England, along with their children.
Originally reported by Nikita Nath on RealityTea.

#housekeepers

Juventus want another attacker, and the Old Lady is not relying heavily on Nicolas Gonzalez, meaning they could sacrifice him in a deal for one of their main summer targets, Alexander Sorloth.
Sorloth is a player the Bianconeri have followed for months, and Luciano Spalletti likes the profile of the Norwegian star. The Juventus manager would therefore be delighted to have him in his squad and could see him as an important addition to the team's attacking options.
Atletico Madrid do not want to sell their best players, but Sorloth could be allowed to leave under the right conditions. The Spanish side remains interested in signing Gonzalez, creating the possibility of a deal that could benefit both clubs.
Gonzalez spent last season on loan at Atletico Madrid and performed well. Diego Simeone is keen to bring him back, while the Argentinian also wants to return to Madrid, making a potential move appealing to the player.
This has created the conditions for the two clubs to potentially swap players. Tuttomercatoweb reveals that Juventus are also considering a swap deal that would see Sorloth become a member of their squad while Gonzalez returns to Atletico Madrid.

#juventus

Johnson & Johnson (NYSE:JNJ) has proposed a whopping $5.5 billion settlement to resolve tens of thousands of lawsuits that allege its baby powder and ‌other talc products cause ovarian cancer. The proposed settlement could finally provide investors with the visibility they have lacked for over a decade into one of the company's largest legal liabilities.
The agreement would resolve approximately 76,000 ovarian cancer claims, but it is not yet final. It requires participation from at least 95% of eligible claimants, does not cover future lawsuits, and could ultimately cost more than the headline figure. For investors, the question is whether the benefit of removing a major legal overhang outweighs the settlement's uncertain final cost.
The talc litigation has followed Johnson & Johnson (NYSE:JNJ) for over a decade, and resolving approximately 76,000 claims would reduce the uncertainty surrounding court verdicts, appeals, and legal expenses. A large but more measurable liability may be preferable to an open-ended series of trials capable of producing unpredictable verdicts.
Johnson & Johnson (NYSE:JNJ) ended fiscal Q2 2026 with approximately $21 billion of cash and marketable securities. The company also raised its full-year guidance and is on track to surpass $100 billion in annual revenue in 2026 for the first time in its 140-year history. The proposed payment is, therefore, substantial but does not appear existential for a company of J&J's scale. In addition, the payout has a staggered structure, with the company expecting to pay up to $3 billion in 2027, followed by additional payments beginning in 2028, which may also reduce the immediate pressure on liquidity.
Furthermore, Johnson & Johnson (NYSE:JNJ) may be settling from a position of improved legal strength as a federal judge cast doubt on individual plaintiffs' ability to prove that talc specifically caused their ovarian cancer. The company thus does not appear to be forced into an agreement following a decisive courtroom defeat.

#billion #Legal #ovarian #approximately

One super talent has agreed a five year contract with Liverpool and handed in a transfer request.
Liverpool need to sign a winger. It is probably one of the clearest priorities facing the club right now.
The departure of Mohamed Salah has left a huge hole in the attack, both in terms of goals and creativity. Replacing someone of Salah's quality was never going to be easy, but Liverpool cannot simply hope that the existing squad can fill the void.
What is missing is someone who can provide genuine width, pace and the ability to beat a defender one-on-one. Liverpool need a winger capable of stretching teams, creating chances from nothing and giving opponents something different to think about.
That becomes even more important under Andoni Iraola. His football relies heavily on intensity, quick transitions and attacking players who are comfortable taking risks. Wingers are therefore not just useful additions to the squad; they are central to how he wants Liverpool to play.

#squad #replacing

Zoetis Inc. (NYSE:ZTS) entered 2026 as a leader in animal health, but its latest earnings show that even a strong market position cannot fully insulate the company from weaker consumer demand. Fiscal Q2 2026 revenue remained flat at $2.5 billion and declined 1% on an organic operational basis, as pressure in the U.S. companion-animal market offset growth in livestock and international markets.
The quarter therefore presents investors with two different versions of Zoetis (NYSE:ZTS), as an established companion-animal business facing near-term pressure and a diversified animal-health platform still investing in its next generation of products.
Zoetis's (NYSE:ZTS) diversification provided an important source of resilience during the quarter. Livestock revenue increased 12% on a reported basis, supported by cattle and poultry products. In the United States, livestock sales grew 23% on both a reported and organic operational basis in the quarter, benefiting from favorable beef-cattle economics, supply timing, and increased poultry-vaccine sales **** ociated with disease outbreaks.
International performance was also encouraging. Revenue outside the United States rose 8% on a reported basis and 6% organically to $1.2 billion. International companion-animal sales grew 5% organically, supported by parasiticides such as Simparica Trio, Revolution and Stronghold, as well as diagnostics and newer osteoarthritis treatments. This geographic contrast demonstrates that the weakness was not uniform across Zoetis's (NYSE:ZTS) business. Demand for its products remains healthy in several markets, even as U.S. pet owners become more price-sensitive.
However, innovation could provide another route back to growth, as Zoetis (NYSE:ZTS) says that its pipeline contains more than 12 potential blockbuster candidates across chronic kidney disease, oncology, cardiology, anxiety, and obesity. The company also launched Lenivia and Portela, long-acting osteoarthritis treatments offering dogs and cats up to three months of pain relief from one injection.

#revenue #quarter

AstraZeneca PLC (NYSE:AZN) is paying $600 million upfront to secure global rights to Zegfrovy from Dizal Pharmaceutical Co., Ltd, adding another targeted therapy to one of the pharmaceutical industry's largest oncology portfolios. Dizal Pharmaceutical could receive an additional $900 million if specified development, regulatory, and sales milestones are achieved, bringing the agreement's potential value to $1.5 billion. Dizal will also receive tiered royalties on the global sales of Zegfrovy.
Zegfrovy, also known as sunvozertinib, is an oral treatment approved in the United States and China for certain adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. Under the agreement, AstraZeneca (NYSE:AZN) will take responsibility for the treatment's global development and commercialisation.
For AstraZeneca (NYSE:AZN) shareholders, the transaction offers an opportunity to ****** s whether another targeted lung-cancer medicine can reinforce the company's oncology leadership, or whether the price adds further execution risk to an already extensive pipeline.
The agreement strengthens AstraZeneca's (NYSE:AZN) position in a therapeutic area where it already has substantial scientific and commercial experience. The company has built a major lung-cancer business around treatments including Tagrisso, Imfinzi, and Enhertu. That existing infrastructure could help AstraZeneca (NYSE:AZN) introduce Zegfrovy to physicians and patients more efficiently than a smaller developer with a limited global presence.
Zegfrovy also addresses a specific group of patients with EGFR exon 20 insertion mutations, for whom treatment options remain limited. In the Phase III WU-KONG28 trial, Zegfrovy produced median progression-free survival of 10.3 months, compared with 7.5 months for chemotherapy. AstraZeneca (NYSE:AZN) therefore gains an approved medicine supported by late-stage comparative evidence rather than an early experimental ****** et whose clinical viability remains largely unknown.

#lung #egfr

Semiconductor solutions provider Marvell Technology (MRVL) has recently risen after a deal was revealed with Google parent Alphabet (GOOG) (GOOGL) that would allow Google to buy $12.20 billion worth of shares in the chipmaker. The partnership builds on the existing deal between the two companies for custom chips.
In a regulatory filing, Marvell stated that the expanded agreement will cover products tied to the tensor processing unit ecosystem, including AI inference accelerators and storage and network interface controllers. Investors are excited about the deal because it shows Marvell's custom‑silicon platform is gaining traction among hyperscalers, which can signal greater revenue visibility down the line. Therefore, the stock may be worth considering now.
Ahead of Nvidia Earnings, Here's What Barchart Data Says Comes Next for NVDA Stock
Soros Fund Management Opened a New Position in Nebius During Q2. What This Means for NBIS Stock.
Nvidia Earnings, Jackson Hole and Other Key Things to Watch this Week

#marvell #semiconductor #technology

While it seems that Democrats and Republicans can't agree on much of anything these days, there's at least one common enemy that's bringing both sides of the aisle together: data centers. Representatives on both sides of the aisle are increasingly pushing back against hyperscalers who are developing massive data center campuses on local energy grids, driving up energy demand and therefore causing electricity prices to skyrocket for everyone, whether they benefit from the artificial intelligence boom or not.
The Trump administration has attempted to resolve the issue by pushing the tech sector to provide its own energy sources to power its rapidly proliferating data centers. But while the legislation ostensibly pushes the responsibility of energy buildout – and the money to support it – back onto the tech firms responsible for skyrocketing energy demand rates in the first place, there is some concern that the policy may yield some considerable and costly unintended consequences.
Trump "essentially envisions a bespoke new power system built in parallel to the existing one," argues a recent op-ed from the energy editor of non-partisan news outlet Semafor. By inviting Big Tech to build its own energy infrastructure, policymakers are inviting the private sector to create a shadow grid that operates outside of the regulations that govern our standard electricity grids, and the oversight mechanisms that ensure compliance with other policy measures, such as environmental protections.
Plus, by encouraging Big Tech to invest in its own energy infrastructure, the country is missing out on a major opportunity to encourage much-needed investment in its own aging grid at a time when more resilience and greater transmission infrastructure is sorely needed. "Most of today's cost pressure is coming from transmission, distribution, and system readiness, not energy supply," Brandon Owens, a grid expert and founder of advisory platform AIxEnergy, was quoted by Politico last week. "Those costs remain even if a data center self-supplies generation."
Despite these concerns, Big Tech is pushing ahead with some truly gargantuan energy infrastructure projects, most of which are being developed in tandem with sprawling data center campuses. Amazon is currently building a gas-fired power plant in Texas that is set to become the single-biggest source of power-related emissions in the entire United States. And just this week, Nvidia announced that it would team up with ****** an's SoftBank and the United States government to build the country's largest fossil-fuel plant to power an OpenAI project in Ohio.

#Trump

Investor optimism has climbed to its third-highest level since 2022, according to Bank of America's August Global Fund Manager Survey, with portfolio cash holdings approaching historic lows and allocations to equities reaching their strongest level in nearly five years.
Cash declined to 3.5% of **** ets under management in August from 3.6% in July, representing the sixth-lowest reading since the survey began in 1998. BofA's Global FMS Cash Rule, which is designed as a contrarian indicator, therefore remains on "sell," as the signal is activated whenever cash allocations fall to 4.0% or below.
At the same time, global equity exposure increased to a net 56% overweight, its highest level since November 2021. Fund managers have now maintained an overweight position in equities for 14 consecutive months.
Confidence in the economic outlook has also strengthened significantly. A record 56% of respondents anticipate a "no landing" scenario, while 43% expect a "boom" outcome, the highest proportion since February 2022.
"Consensus conviction is no macro landing, no Fed hike, no AI capex cut, no DEM sweep, no bears," BofA strategists led by Michael Hartnett said in a note.

#since #august #allocations

Pudgy Penguins token PENGU climbed 62.1% over the past week and now trades near $0.0095. Traders link a cryptic post from CEO Luca Netz to the company's stated ambition of a public listing.
The token added roughly 15% in the last 24 hours alone. Meanwhile, its market value sits close to $598 million, ranking PENGU 97th across all cryptocurrencies.
LBank, a centralized crypto exchange, opened a promotional campaign with Pudgy Penguins in August. The program combines trading competitions, giveaways, and yield products that lock user deposits for 30 days. Those locked products keep tokens away from exchange order books for a month at a time. Therefore, the campaign thins the supply available to sellers while it runs.
The brand keeps widening its offline footprint too. Plush toys and collectible figures now sell through Walmart and Target stores across North America. Netz pushed the Target rollout directly to his followers this weekend.
Retail distribution has become the core bull case here. In January, the project moved deeper into sports through its Manchester City NFT deal. That pivot matters more now, because the wider NFT market cap slide has hit blue-chip collections hard this year.

#netz #target #across #campaign

Microsoft Corporation (NASDAQ:MSFT)'s shares have witnessed a major turnaround in 2026. They are up by 2% year-to-date, primarily on the back of 23.7% gain since late July. The shares closed a strong 15.5% higher on July 30th, the day after Microsoft Corporation (NASDAQ:MSFT) reported its fiscal fourth quarter earnings. The results saw the firm beat ***** yst revenue and earnings estimates, and more importantly, its Azure cloud computing business saw revenue jump by 43% annually to beat even the most optimistic ***** yst estimates. With investors focused on AI returns, Microsoft Corporation (NASDAQ:MSFT)'s shares were rewarded. On August 17th, Cramer discussed the earnings and their impact:
"Yeah that's gutsy. I think a lot of people hanging their hat on that. Because, they do so much good work. But, of the, of the Magnificent 7, that's the one that, I think is still kind of vulnerable. After Microsoft did that tour de force conference call. The Microsoft conference call was maybe the best conference call in the quarter. Because it turned a huge cohort of people in favor of it versus against it. We didn't see that with Google and we're still waiting for it with Meta. I still believe that if Mark Zuckerberg wanted to, he could take that stock off the near 52 week low. . .and turn it around. But he needs to say, you know what, I've really thought about this. And we're going to rent out. Because we have so much demand and then they name like three companies that need some of their cloud business. I wish they could finish that thing in Louisiana."
Additionally, Microsoft Corporation (NASDAQ:MSFT) shared two key updates for its cloud computing and AI initiatives. The firm guided 45% in Azure growth for the first quarter to beat estimates. CEO Satya Nadella also remarked that Microsoft Corporation (NASDAQ:MSFT) had achieved efficiency gains of as much as 40% through using custom chips and external AI technologies. Overall, the firm's operating margin sat at 45% to fuel the bullish viewpoint of AI profitability and strong execution.Commercial bookings decelerated to 12% as CapEx jumped 35% ($13.87B), driving a 23% drop in free cash flow and signaling margin compression risks.
Commercial bookings decelerated to 12% as CapEx jumped 35% ($13.87B), driving a 23% drop in free cash flow and signaling margin compression risks.
As for Meta Platforms, Inc. (NASDAQ:META), the shares are down by 15.5% year-to-date. As is the case with MSFT, the debate for the firm is also about AI and whether the spending will yield results. However, unlike MSFT, Meta Platforms, Inc. (NASDAQ:META) does not have a cloud computing business. Therefore, all focus is on its advertising business and the tailwinds it generates courtesy of AI. Naturally, Cramer also discussed this aspect as he commented on the firm renting out cloud capacity. Overall, the firm's Q2 advertising revenue jumped by 27% while its ad impressions jumped by 14% and the firm guided as much as 17% annual growth

Financial technology firms' SoFi Technologies, Inc. (NASDAQ:SOFI) and PayPal Holdings, Inc. (NASDAQ:PYPL)'s shares have diverged in performance in 2026. SOFI is down by 31% year-to-date while PYPL is up by 5.9%. PayPal Holdings, Inc. (NASDAQ:PYPL)'s stock has gained primarily on the back of takeover news, but Cramer has remained unconvinced. In his previous remarks about the firm, the CNBC TV host remarked that he was hesitant to recommend the stock on the basis of takeover news. In his morning appearance on August 17th, Cramer admonished **** ysts for recommending the stocks even though they were struggling:
"One of the more irritating parts of this market is, the insistence of loving fintech. The **** ysts just love fintech. And the three that they love are SoFi, Klarna, and now PayPal. Look, I totally understand it. But you don't need to reiterate every day people. We understand. PayPal maybe a takeover candidate. Klarna is doing really great. SoFi, it's going to come back. Just stop. **** ysts stop recommending these. Let them go to where they are on the downside. And then you can recommend them. . .I really think that's what happened is that, thatPayPal, when we heard that it might get a takeover bid, it made everything really exciting to people. But I just think, no, just go buy Wells Fargo. Go buy JPMorgan over Klarna. Okay. Or over PayPal."
SoFi Technologies, Inc. (NASDAQ:SOFI)'s narrative surrounds its valuation. The firm's forward P/E ratio is 31.55, which is nearly double that of banking giant JPMorgan and more than 2x of PYPL's 11.79. The risk to SoFi Technologies, Inc. (NASDAQ:SOFI)'s valuation comes from its transformation into a digital bank from a student loan company. Therefore, the firm's Financial Services and Technology platforms are at the center of the narrative.
On this front, SoFi Technologies, Inc. (NASDAQ:SOFI)'s second quarter saw its two businesses grow net revenue by 29% and drop by 23% annually. Technology suffered as a large client transitioned away from the platform. SoFi Technologies, Inc. (NASDAQ:SOFI)'s management added that the two businesses should account for more than 50% of overall revenue over the long term. To sum it up, the firm's headwinds could stem from high deposit costs of sizable amount of funds, such as $45 billion in the latest quarter, while the capital light Financial Services business and fee-driven Technology Services could lead the way to growth.
Shifting towards PayPal Holdings, Inc. (NASDAQ:PYPL), it's all about turnaround versus acquisitions. The turnaround camp, of which its management is also a part of, hinges on improved checkout performance, AI modernization, cost savings and Venmo growth. Through these, PayPal Holdings, Inc. (NASDAQ:PYPL) aims to save $400 million in costs in 2026 and streamline headcount in 2027. Therefore, the firm could experience tailwinds should it achieve the stated $1.5 billion in gross run rate savings and generate earnings power.

#NASDAQ #paypal

Manchester United may stand a genuine chance at landing Alejandro Balde, who is now willing to leave Barcelona.
The Red Devils have practically finalised their midfield revamp, as they're about to add Carlos Baleba to their squad. The Cameroonian will join Andrey Santos and Youri Tielemans, who signed for United last month.
Therefore, INEOS can now primarily focus on recruiting a new left-back in the final days of the summer transfer window.
At the start of the summer, United were keen to buy Lewis Hall, identifying him as the perfect long-term replacement for Luke Shaw. However, Newcastle United refused to negotiate a deal with their rivals, especially after selling three key players already: Sandro Tonali, Anthony Gordon, and Bruno Guimaraes.
Therefore, Man Utd have turned to alternative solutions, including Balde, who has been unsettled in Catalunya.

#balde #alejandro #baleba

Wide receiver Terry McLaurin, also known as "Scary Terry," could be a scary addition to your fantasy lineup this season. He has put up elite numbers over the course of his career, especially in 2024 when he had over 1,000 receiving yards and 13 touchdowns. While McLaurin missed seven games last season, ESPN fantasy ****** yst Eric Moody believes he is a great fantasy option this season. Here is what Moody had to say about McLaurin:
"McLaurin is one of my favorite values at wide receiver. In 2024, he scored 13 touchdowns, finished as the WR7 and topped 1,000 yards for the fifth straight season. Last season was basically lost, with McLaurin missing seven games and QB Jayden Daniels missing 10. New OC David Blough has talked about getting McLaurin 10 targets per game, a significant jump from the 7.3 he has averaged over his career, while also moving him around the formation. New signing Stefon Diggs adds competition, but I'm getting a receiver who has already shown WR1 upside at a back-end WR2 price. That's a discount I'm willing to bet on."
Diggs may provide some competition, but he could actually help McLaurin's fantasy stock in a way. Without Diggs, McLaurin was the clear No. 1 receiver on Washington's roster, making him more likely to get double-teamed and have fewer fantasy points. With another elite wide receiver for defenses to worry about, this should lead to more opportunities for McLaurin.
As Moody notes, McLaurin has a current average draft position (ADP) of No. 23 wide receiver. Therefore, you do not have to spend a first or second round pick on him even though he has the potential of a WR1, allowing you to build up other positions on your roster.
The biggest concern with McLaurin is Daniels' health. Some may be worried about McLaurin's health given he missed seven games last season, but he is not injury-prone. In fact, last season was the first time McLaurin missed any time since 2020. Daniels, on the other hand, missed 10 games with three different injuries last season. If he goes down, McLaurin's fantasy production could suffer. But if Daniels is able to remain healthy as he did in 2024, McLaurin could have a monster fantasy season.

#fantasy #last #missed

The Dutch Grand Prix is bidding goodbye to Formula 1 on Sunday but its organizers say it could potentially "serve as an alternative venue" in the future amid continuing uncertainty over next year's schedule.
Already this year, the security situation in the Middle East following the outbreak of the Iran war has meant Bahrain's race was moved to Malaysia and the Saudi Arabian Grand Prix was canceled.
F1 has indicated at least one extra event in Europe if the season-ending races in Qatar and Abu Dhabi can't take place as planned. One likely candidate could be the Imola circuit in Italy. There are more question marks over how the four contracted Middle East races could be included in the 2027 schedule.
"Circuit Zandvoort could serve as an alternative venue in the future if another Grand Prix were unable to take place due to geopolitical circumstances, for example. The circuit's FIA Grade 1 license will remain valid for another three years," the Dutch Grand Prix organization told The ******* ociated Press in a statement Saturday.
"In practice, however, many factors would need to be considered, including the necessary permits, the availability of equipment and the required preparation time. Moreover, there are other venues on the Formula 1 calendar that would make more sense from a logistical perspective. At this stage, therefore, this is not a concrete scenario."

#formula #alternative #venue

Tim Binder has sustained a minor muscle tear in his right hamstring, as confirmed following examination by FC Bayern's medical department. The 19-year-old midfielder is therefore set for a spell on the sidelines.
Warum der Sieg in Dortmund der perfekte FC Bayern-Saisonstart ist

#binder #dortmund

All summer, the future of Claudio Echeverri appeared uncertain. The Argentinian playmaker endured a frustrating 2025-26 season. He went against Manchester City's advice to join Bayer Leverkusen on loan for the first half of last season. That move didn't pan out as Echeverri couldn't force his way into the Leverkusen lineup. He returned to City last January before being sent out on loan to Girona. Manchester City wanted Echeverri to spend last season at Girona. He showed flashes of quality while being used primarily as an impact substitute. Echeverri was a part of Manchester City's preseason tour of Asia where he showed brief glimpses of his talent.
Where Echeverri would play his football during the 2026-27 season hasn't been clear. Perhaps, until now. A new report indicates that Echeverri is set to stay at Manchester City for at least the first half of the 2026-27 season. Echeverri does have attributes that could be useful for Enzo Maresca's side, so it may be a wise move to keep him at City for the time being.
Soy del Millo has reported that Enzo Maresca reportedly wants to give Claudio Echeverri minutes at Manchester City this season. Therefore, Maresca has decided that the young Argentinian excitement machine will not be sent out on loan. As per the Spy del Millo report Enzo Maresca wanted to ***** s Echeverri as a player during Manchester City's preseason. Based on Maresca's ***** sment, Echeverri is set to stay at Manchester City where his progress will be closely monitored.
Typically, Claudio Echeverri operates as a number ten or as an attacking midfielder. Echeverri's clear strength is his ability to drive at defenders with his electrifying pace and mesmerizing dribbling ability. Claudio Echeverri can also pick out a defence splitting pass and he can create opportunities to score for himself and his teammates. Those attributes could be useful to Enzo Maresca's side. Echeverri's strongest attributes could also see him also play on either wing when required.
If, as reported, Claudio Echeverri remains at Manchester City for next season, it wouldn't be expected that he would be a starter. However, as a squad player, he could fulfil a role. Playing as an impact substitute against tired opponents could be in Echeverri's wheelhouse. His pace and ability to make something out of nothing could be useful for Enzo Maresca. That could be his role today as Manchester City take on Bournemouth given that City are short of options on the bench as they await to complete Enzo Maresca's squad in the transfer market.

#attributes

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has released topline results from the Phase 3 LUCIDITY trial of avexitide on August 18, 2026. Shares closed Monday down 0.9% at $21.43, then traded 15.7% higher at $24.80 after hours after the company scheduled the readout. The rally came before investors saw any efficacy or safety data, underscoring how much hope is attached to one event. For Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), the question is whether a successful metabolic-disease trial can finally replace the failed ALS narrative that has defined the company since Relyvrio was withdrawn.
LUCIDITY randomized 78 adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery in a 3:2 ratio to receive once-daily avexitide or placebo. The FDA-agreed primary outcome measures the reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. Avexitide is designed to block the exaggerated GLP-1 response that can drive excess insulin secretion and dangerous drops in blood glucose.
The trial is therefore more than another pipeline update. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) currently has no approved product, and avexitide is its most advanced near-term opportunity to rebuild a commercial business. A positive result would validate the company's move into endocrine disease. A miss would return attention to earlier-stage programs that cannot replace a late-stage **** et quickly.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) enters the readout with supportive early evidence. Amylyx said five earlier Phase 1 and Phase 2 studies produced consistent signals. In a 28-day, open-label Phase 2b crossover study involving 16 patients who had undergone Roux-en-Y gastric bypass or other upper gastrointestinal surgeries, the 90 mg once-daily dose now used in LUCIDITY reduced Level 2 events by 53% and Level 3 events by 66% against the medical nutrition therapy-only run-in baseline. Avexitide was generally well tolerated across prior studies.
The FDA has granted avexitide Breakthrough Therapy designation for post-bariatric hypoglycemia, and management anticipates a potential 2027 launch if the drug is approved. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) held $250.8 million in cash, cash equivalents, and short-term investments as of June 30. Based on its current operating plans, Amylyx expects that amount to provide a cash runway into 2028, supporting a potential regulatory filing and commercial preparations.

#pharmaceuticals #NASDAQ

BitFuFu Inc. (NASDAQ:FUFU) reported a quarter that exposed the difference between producing more Bitcoin and making more money from it. Second-quarter revenue fell 62.9% year over year to $42.8 million, while a $20.5 million net loss replaced a $47.1 million profit. Yet average hashrate allocated to self-mining rose 47%, helping lift self-mined production 34% to 192 Bitcoin. Shares closed 11% lower at $1.29 on August 17 after the results. For BitFuFu Inc. (NASDAQ:FUFU), the question is whether shifting more computing power toward self-mining creates operating leverage or simply increases its exposure to Bitcoin prices and network difficulty.
The largest hole was cloud mining, historically the company's biggest revenue source. Cloud Mining Solutions revenue plunged 73.6% to $24.9 million. BitFuFu attributed the decline to lower selling prices amid falling Bitcoin prices, weaker market sentiment, and reduced order volumes from existing customers. The company reported net dollar retention of 24.1%, calculated as second-quarter 2026 recurring revenue divided by total second-quarter 2025 Cloud Mining revenue. Equipment sales also fell to zero from $5.2 million. The cloud-mining decline overwhelmed the benefit of BitFuFu Inc. (NASDAQ:FUFU) allocating more hashrate to self-mining.
Self-mining was hardly immune. Revenue declined to $14.0 million from $14.8 million even as production increased. BitFuFu attributed the decline to the combined effect of a 27.5% drop in the average Bitcoin price to $71,600 and higher network difficulty, partially offset by the increased self-mining allocation. Network difficulty reduced daily Bitcoin earned per terahash by 9.7%. Cost of revenue reached $43.7 million, exceeding total revenue. A $16.9 million net fair-value loss on digital ***** ets and digital-asset receivables or payables significantly affected company-defined adjusted EBITDA, a non-GAAP measure, which was negative $18.4 million. BitFuFu Inc. (NASDAQ:FUFU) therefore suffered from both weaker operating economics and an adverse accounting swing.
BitFuFu Inc. (NASDAQ:FUFU) produced more Bitcoin despite the harsher environment, deployed next-generation S21 XP miners, and restored total managed hashrate to approximately 20 EH/s by mid-August from 15.3 EH/s at quarter-end. Hosting and other revenue also rose to $3.9 million from $1.1 million. If Bitcoin prices recover while difficulty and power costs become more favorable, the larger self-mining allocation could turn higher production into a much stronger revenue and earnings response.

#bitfufu #self #NASDAQ #cloud